Clinical Trials Browser

Phase 2 × Recurrence × sintilimab × Clear all

NCT03989336 2024-07-15

A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

Phase 2 Completed

Ovarian Neoplasms, Recurrence